Dr. Zode's research project recommended for $250,000 in dunding through TRxA

Dr. Zode’s research project, “Lipid Nanoparticle-Mediated Base Editing of Human MYOC for Treatment of Juvenile-Onset Glaucoma,” has been recommended for $250,000 in funding and collaborative support through the Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA). Selected from a competitive pool of 75 applications, the project aims to advance innovative gene-editing approaches for treating juvenile-onset glaucoma.

The proposed research focuses on developing a targeted base-editing strategy to address mutations in the MYOC gene, which are associated with inherited forms of glaucoma. By utilizing lipid nanoparticles (LNPs) to deliver gene-editing components, the project seeks to identify and optimize a candidate guide RNA capable of targeting human MYOC. Researchers will evaluate the approach in human trabecular meshwork cells and a humanized mouse model of MYOC-associated glaucoma to assess its potential efficacy, durability, and safety.

The funding recommendation follows a review by TRxA’s Scientific Advisory Committee and Programmatic Review Board. The proposed support will help advance critical preclinical research and establish a foundation for developing more precise, targeted treatments for patients affected by inherited glaucoma.

This recognition highlights the importance of innovative genetic research in addressing vision-threatening diseases and represents a promising step toward translating gene-editing technologies into future therapeutic applications.